Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results
Key Highlights
- ➤Revenue $206.7 million, down 7.9% year over year
- ➤Diluted EPS $(0.84); adjusted diluted EPS $0.14
- ➤2026 revenue guidance narrowed to $850 million-$860 million
- ➤Operating expenses rose 12.8%, including $24.1 million restructuring charges
- ➤New Category I CPT codes for single-lead HGNS take effect January 1, 2028
Expert Statements
Tim Herbert, Chairman and CEO of Inspire Medical Systems
“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic. We will stay disciplined in our education initiatives and focused on executing our strategic priorities as we finish out 2026 and plan for a return to growth in 2027.”
Tim Herbert, Chairman and CEO of Inspire Medical Systems
“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy. With that progress, and the investment capacity we’re redirecting into high-impact revenue growth initiatives through Project Horizon, we believe we are positioned well for growth in the years ahead.”
* Third quarter revenue of $206.7 million * Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14 * Third quarter operating cash flow of $46.4 million * AMA CPT® Editorial Panel approved new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028 MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2026.
“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic. We will stay disciplined in our education initiatives and focused on executing our strategic priorities as we finish out 2026 and plan for a return to growth in 2027,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.
Get started
Create a free account to read the full story.